Unique ID issued by UMIN | UMIN000049339 |
---|---|
Receipt number | R000056044 |
Scientific Title | Safety-verification of a long-term test-food consumption |
Date of disclosure of the study information | 2023/11/02 |
Last modified on | 2024/05/20 15:59:14 |
Safety-verification of a long-term test-food consumption
Safety-verification of a long-term test-food consumption
Safety-verification of a long-term test-food consumption
Safety-verification of a long-term test-food consumption
Japan |
Healthy adults
Adult |
Others
NO
To validate whether a long-term test-food consumption (12 weeks) of the amount of recommended ingestion per day could have sufficient safety.
Safety
Incidence of some kind of adverse event and/or side effect, and changes in clinical examination values.
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Prevention
Food |
Consumption of the test food (a package/day) to the subjects for 12 weeks.
20 | years-old | <= |
65 | years-old | > |
Male and Female
(1) Healthy male/female subjects ranging in age from 20 to 64, at the moment of giving informed consent to partake in this trial.
(2) Subjects who can give informed consent to take part in this trial after being provided with an explanation of our experimental protocol detail.
(1) Subjects who take steadily in anthocyanin-rich health-specific/functional/supplementary/health foods, and will have any difficulty in giving up taking them after the consent.
(2) Subjects who have taken some kind of medicine, and have any difficulty in refraining from taking them during this trial.
(3) Subjects with excessive alcohol intake.
(4) Subjects with current and/or previous medical history of serious diseases in heart, liver, kidney and/or digestive organs.
(5) Pregnant, lactating women, and possibly pregnant ones during this trial.
(6) Subjects with drug and/or food allergy.
(7) Subjects who are now under other clinical trials with some kind of medicine/food, or partook in those within four weeks before this trial, or planning to join those after the consent.
(8) Subjects who donated over 200 mL of their blood and/or blood components within a month to this trial.
(9) Males who donated their whole blood (400 mL) within the last three months to this trial.
(10) Females who donated their whole blood (400 mL) within the last four months to this trial.
(11) Males who will be collected in total of their blood (1200 mL) within the last twelve months, after adding the blood amounts planning to be sampled in this trial.
(12) Females who will be collected in total of their blood (800 mL) within the last twelve months, after adding the blood amounts planning to be sampled in this trial.
(13) Others who have been determined as ineligible for participation in this trial, according to the principal/sub investigator's opinions.
15
1st name | Akihisa |
Middle name | |
Last name | Tsuji |
TSUJIKO Co., Ltd.
Representative Director
528-0057
1750-1 Kitawaki, Minakuchi-Cho, Kouka-shi, Shiga 528-0057, Japan
0748-62-2233
akitsuji@tsujiko.com
1st name | Masanori |
Middle name | |
Last name | Numa |
CPCC Company Limited
Clinical Planning Department
103-0021
4F Daiwa Building, 3-3-10 Nihonbashi-Hongoku-Cho, Chuo-ku, Tokyo 103-0021, Japan
03-6225-9001
cpcc-contact@cpcc.co.jp
CPCC Company Limited
TSUJIKO Co., Ltd.
Profit organization
Institutional Review Board of Chiyoda Paramedical Care Clinic
2F Daiwa Building, 3-3-10 Nihonbashi-Hongoku-Cho, Chuo-ku, Tokyo 103-0021, Japan
03-6225-9005
IRB@cpcc.co.jp
NO
2023 | Year | 11 | Month | 02 | Day |
Unpublished
Completed
2022 | Year | 10 | Month | 24 | Day |
2022 | Year | 10 | Month | 21 | Day |
2022 | Year | 11 | Month | 02 | Day |
2023 | Year | 02 | Month | 15 | Day |
2022 | Year | 10 | Month | 27 | Day |
2024 | Year | 05 | Month | 20 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000056044